Liver Cirrhosis Research Today is a free monthly online journal that collates and summarizes the latest research about Liver Cirrhosis, including details on alcohol, treatment, drugs, effects, causes.

Volume 4 (2007), Issue 4 (April)

1. Liver biopsy in cirrhotic patients.
   Am J Gastroenterol, 102(4): 789-93. [Abstract] [Full-text]
2. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial.
   Am J Gastroenterol, 102(4): 744-53. [Abstract] [Full-text]
3. Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model.
   Liver Int, 27(4): 548-57. [Abstract] [Full-text]
4. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis.
   Liver Int, 27(4): 498-506. [Abstract] [Full-text]
5. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
   Liver Int, 27(4): 492-7. [Abstract] [Full-text]
6. Liver fibrosis: searching for cell model answers.
   Liver Int, 27(4): 434-9. [Abstract] [Full-text]
7. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis.
   Hepatology, 45(4): 886-94. [Abstract] [Full-text]
8. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy.
   Hepatology, 45(4): 879-85. [Abstract] [Full-text]
9. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
   Hepatology, 45(4): 846-54. [Abstract] [Full-text]
10. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis.
    Hepatology, 45(4): 977-81. [Abstract] [Full-text]
11. Vitamin E supplementation reverses renal altered vascular reactivity in chronic bile duct-ligated rats.
    Am J Physiol Regul Integr Comp Physiol, 292(4): R1486-93. [Abstract] [Full-text]
12. Transgenic expression of osteoactivin in the liver attenuates hepatic fibrosis in rats.
    Biochem Biophys Res Commun, 356(3): 610-5. [Abstract] [Full-text]
13. Early central catheter infections may contribute to hepatic fibrosis in children receiving long-term parenteral nutrition.
    J Pediatr Gastroenterol Nutr, 44(4): 459-63. [Abstract] [Full-text]
14. Reversal of liver cirrhosis: a desirable clinical outcome and its pathogenic background.
    J Pediatr Gastroenterol Nutr, 44(4): 401-6. [Abstract] [Full-text]
15. A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C.
    J Clin Gastroenterol, 41(4): 416-21. [Abstract] [Full-text]
16. The model for end-stage liver disease (MELD) predicts survival of liver cirrhosis patients after discharge to hospice.
    J Clin Gastroenterol, 41(4): 412-5. [Abstract] [Full-text]
17. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study.
    Eur J Gastroenterol Hepatol, 19(5): 425-31. [Abstract] [Full-text]
18. Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment.
    Dig Liver Dis, 39(5): 490-4. [Abstract] [Full-text]
19. Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis.
    Clin Sci (Lond), 112(10): 533-42. [Abstract] [Full-text]
20. Liver transplantation in children with sickle-cell disease.
    Liver Transpl, 13(4): 505-8. [Abstract] [Full-text]
21. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.
    Clin Exp Immunol, 148(1): 85-9. [Abstract] [Full-text]
22. Lymphocyte-hepatic stellate cell proximity suggests a direct interaction.
    Clin Exp Immunol, 148(2): 338-47. [Abstract] [Full-text]
23. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats.
    J Pharmacol Exp Ther, 321(2): 536-43. [Abstract] [Full-text]
24. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.
    J Viral Hepat, 14(5): 360-9. [Abstract] [Full-text]
25. Human serum fetuin A/alpha2HS-glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores.
    BMC Gastroenterol, 7: 15. [Abstract] [Full-text]
26. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis.
    Dig Dis Sci, 52(5): 1187-93. [Abstract] [Full-text]
27. Gastric tissue oxidative changes in portal hypertension and cirrhosis.
    Dig Dis Sci, 52(5): 1154-8. [Abstract] [Full-text]
28. Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation.
    Lab Invest, 87(5): 499-514. [Abstract] [Full-text]
29. Heterozygous beta-globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C.
    Gut, 56(5): 693-8. [Abstract] [Full-text]
30. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats.
    Gut, 56(5): 706-14. [Abstract] [Full-text]
31. Increased frequencies of activating natural killer receptors are associated with liver injury in individuals who do not eliminate hepatitis C virus.
    Tissue Antigens, 69: 109-11. [Abstract] [Full-text]
32. Oxidative-inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation.
    J Gastroenterol Hepatol, 22(5): 697-703. [Abstract] [Full-text]
33. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
    J Gastroenterol Hepatol, 22(5): 634-8. [Abstract] [Full-text]
34. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
    Clin Gastroenterol Hepatol, 5(4): 502-7. [Abstract] [Full-text]
35. Enhancement of the liver on dynamic MDCT: investigation among three groups consisting of noncirrhotic patients and cirrhotic patients with and without a large portosystemic shunt.
    Radiat Med, 25(3): 106-12. [Abstract] [Full-text]
36. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy.
    J Clin Gastroenterol, 41(5): 494-500. [Abstract] [Full-text]
37. Focal nodular hyperplasia-like nodules in alcoholic liver cirrhosis: radiologic-pathologic correlation.
    AJR Am J Roentgenol, 188(5): W459-63. [Abstract] [Full-text]
38. Assessing routine and serum markers of liver fibrosis in CHB patients using parallel and serial interpretation.
    Clin Biochem, 40(8): 562-6. [Abstract] [Full-text]
39. Probing the mRNA processing body using protein macroarrays and "autoantigenomics".
    RNA, 13(5): 704-12. [Abstract] [Full-text]
40. Partial Splenic Embolization: successful treatment of hypersplenism, secondary to biliary cirrhosis and portal hypertension in cystic fibrosis.
    J Cyst Fibros, 6(3): 212-4. [Abstract] [Full-text]
41. Evaluation of the protective effects of quercetin in the hepatopulmonary syndrome.
    Food Chem Toxicol, 45(7): 1140-6. [Abstract] [Full-text]
42. Alcohol dehydrogenase and aldehyde dehydrogenase gene polymorphism in alcohol liver cirrhosis and alcohol chronic pancreatitis among Polish individuals.
    Scand J Gastroenterol, 42(4): 493-8. [Abstract] [Full-text]
43. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients.
    Radiol Med (Torino), 112(3): 394-408. [Abstract] [Full-text]
44. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
    Am J Surg Pathol, 31(5): 681-9. [Abstract] [Full-text]
45. Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease.
    J Gastroenterol, 42(4): 312-7. [Abstract] [Full-text]
46. Risk factors for mortality after surgery in patients with cirrhosis.
    Gastroenterology, 132(4): 1261-9. [Abstract] [Full-text]
47. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells.
    Gastroenterology, 132(4): 1434-46. [Abstract] [Full-text]
48. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4.
    Diabetes Care, 30(5): 1168-72. [Abstract] [Full-text]

© 2004-2008 Liver Cirrhosis Research Today. All Rights Reserved.